Earnings Releases·Nov 9, 2026, 4:08 PM ET

Larimar Therapeutics — November 2026 Earnings Summary

Completed rolling BLA submission to FDA for accelerated approval of nomlabofusp for Friedreich's ataxia, targeting U.S. approval in mid-2027 and a potential Q3 2027 launch.
Anticipates BLA acceptance in early 2027 and aims to monetize a Rare Pediatric Disease Priority Review Voucher in mid-2027 if approval is granted.
Nomlabofusp holds FDA Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug designations, with no approved therapies currently available for children under 16 with FA.
Management expressed confidence in the program based on sustained increases in skin frataxin and directional clinical improvements, while noting the FDA may require additional data or reject the proposed surrogate endpoint.
Company is evaluating options to optimize its global commercialization strategy and plans to utilize its intracellular delivery platform for future rare disease programs.